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Thyroid hormones affect the heart and cardiovascular
function through many direct and indirect mechanisms.
Symptoms related to the cardiovascular effects are very
common and they are generally the ﬁrst warning signs,
alarming the patient and requiring diagnosis and treatment.
Ertek and Cicero [1] have recently and extensively reviewed
the relationship between hyperthyroidism and cardiovas-
cular complications. In synthesis, in hyperthyroid patients,
we can observe increased stroke volume due to increased
preload (mainly related to sodium retention) and decreased
afterload due to decreased systemic vascular resistance and,
ﬁnally, increased myocardial contractility and heart rate
related to sympathetic system activation. Sinusal tachy-
cardia, atrial ﬁbrillation and tachyarythmias, widened blood
pressure and decreased exercise tolerance are common
symptoms. Ischemic heart disease can be precipitated in
patients with underlying diseases and thyrotoxic cardio-
myopathy can occur in end stage, poorly treated patients.
Kaminski G et al. [2] have recently shown that patients
with subclinical hyperthyroidism had lower exercise toler-
ance, larger end diastolic and end systolic volume indexes,
and increased stroke volume, positively correlated to thyr-
oid hormones concentrations. According to the results of
their study, they conclude that cardiovascular alterations are
common in subclinical hyperthyroidism. Subclinical
hyperthyroidism is a deﬁnition, but not a syndrome with
speciﬁc clinical features. This is not a semantic distinction
but refers to the difﬁculty of justifying the presence of
suppressed thyroid-stimulating hormone (TSH) levels in
presence of FT3 and FT4 values within the normal range.
The confusion derives from the intrinsically equivocal
method for deﬁning a normal range. A reference range is
deﬁned as the prediction interval containing the 95 % of
values of a reference group [3]. In such a way, 2.5 % of
sample values will be less than the lower limit and 2.5 %
larger than the upper limit. Assuming a normal distribution,
the 95 % prediction interval can be deﬁned as the interval
limited by two standard deviations from either side of the
population mean. In this case, the thresholds values identify
three discrete intervals of thyroid hormones levels, which
discriminate normals from patients with hypo or hyper-
thyroidism. This distinction is somewhat artiﬁcial as in the
global population the distribution of blood concentrations of
thyroid hormones is not a discrete but a continuous variable
and the median value of patients with so called “subclinical
hyperthyroidism” would be certainly different from that of a
reference population. The results of the study of Kaminski
G et al. reinforce the concept that patients with suppressed
TSH but FT4 and FT3 in the normal range show similar
cardiovascular parameters as in overt hyperthyroidism and
for this reason they have decided to adequately treat their
patients with normalization of indexes of cardiac function,
avoiding further cardiovascular complications. Atrial
ﬁbrillation frequently occurs in older patients. In people
over 60 years of age subclinical hyperthyroidism is asso-
ciated with tripled risk of atrial ﬁbrillation during a 10-year
follow-up period [4] and increased cardiovascular mortality
[5] as underlined in the discussion of the paper of Kaminski
G et al.
A major concern that could be raised on their study is the
methodology they have adopted for evaluating left ven-
tricular function. Their patients underwent stress/rest
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myocardial perfusion imaging with 740MBq of 99 m-
technetium labeled compounds delivering an effective dose
of 12 mSv, without adopting technologies for dose con-
tainment. According to the Choosing Wisely campaign,
endorsed by the American Society of Nuclear Cardiology,
physicians should not perform cardiac imaging for patients
who are at low risk of ischemic heart disease and, in any
case, they should use, whenever possible, methods to
reduce radiation exposure, including not performing such
tests when limited beneﬁts are likely [6]. No patient of the
study group had an imaging test positive for myocardial
ischemia and all the functional parameters reported in the
study could have been obtained by alternative methods, like
ultrasound, without exposing the patients to ionizing
radiations. It is therefore advisable that the procedure
adopted in this study, justiﬁed for research purposes, will be
not part of routine evaluation of subjects with “subclinical
hypothyroidism”.
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